Landos Biopharma, Inc.Landos Biopharma, Inc.Landos Biopharma, Inc.

Landos Biopharma, Inc.

No trades
See on Supercharts
Market capitalization
‪68.06 M‬USD
−3.49USD
‪−21.94 M‬USD
‪2.81 M‬
Beta (1Y)
0.83

About Landos Biopharma, Inc.

CEO
Gregory Oakes
Headquarters
Blacksburg
Employees (FY)
19
Founded
2017
FIGI
BBG00HT2F2R6
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of LABP is 21.96 USD — it has increased by 0.64% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Landos Biopharma, Inc. stocks are traded under the ticker LABP.
Landos Biopharma, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
LABP stock is 2.24% volatile and has beta coefficient of 0.83. Check out the list of the most volatile stocks — is Landos Biopharma, Inc. there?
One year price forecast for Landos Biopharma, Inc. has a max estimate of 20.42 USD and a min estimate of 3.25 USD.
LABP earnings for the last quarter are −0.94 USD per share, whereas the estimation was −0.89 USD resulting in a −6.21% surprise. The estimated earnings for the next quarter are −0.92 USD per share. See more details about Landos Biopharma, Inc. earnings.
Landos Biopharma, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪9.00 M‬ USD.
Yes, you can track Landos Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
LABP stock has risen by 2.09% compared to the previous week, the month change is a 185.19% rise, over the last year Landos Biopharma, Inc. has showed a 657.24% increase.
LABP net income for the last quarter is ‪−6.12 M‬ USD, while the quarter before that showed ‪−5.86 M‬ USD of net income which accounts for −4.42% change. Track more Landos Biopharma, Inc. financial stats to get the full picture.
Today Landos Biopharma, Inc. has the market capitalization of ‪68.50 M‬, it has increased by 0.14% over the last week.
No, LABP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, LABP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Landos Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
LABP reached its all-time high on Mar 2, 2021 with the price of 169.89 USD, and its all-time low was 2.11 USD and was reached on Nov 30, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 23, 2024, the company has 19.00 employees. See our rating of the largest employees — is Landos Biopharma, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Landos Biopharma, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Landos Biopharma, Inc. stock shows the buy signal. See more of Landos Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Landos Biopharma, Inc. future price: according to them, LABP price has a max estimate of 20.42 USD and a min estimate of 3.25 USD. Read a more detailed Landos Biopharma, Inc. forecast: see what analysts think of Landos Biopharma, Inc. and suggest that you do with its stocks.